Factors influencing superficial and deep vein thrombosis after foam sclerotherapy in varicose veins.
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
19
02
2021
accepted:
21
01
2022
pubmed:
13
6
2022
medline:
29
7
2022
entrez:
12
6
2022
Statut:
ppublish
Résumé
Side effects of foam sclerotherapy for varicose veins can include both deep (DVT) and superficial leg vein thrombosis (SVT). The risk factors that favor the development of SVT or DVT after foam sclerotherapy are still largely unclear. The aim of our retrospective analysis was to use a larger group of patients with thromboembolic complications to identify both patient-related and procedure-related risk factors for thromboembolic complications from foam sclerotherapy. A total of 170 patients who received foam sclerotherapy were examined. With reference to a cut-off date, March 17th, 2020, the 85 most recent patients with thromboembolic complications (study group A) were included and compared to the most recent 85 patients without thromboembolic complications (control group B), after sclerotherapy with foamed sclerosant. Patients with a thromboembolic complication were more likely to have thrombophilia (11/85 vs. 3/85). The mean BMI values in group A (25.9 ± 5.1) were significantly lower than in group B (28.0 ± 7.2) (P = 0.034). Thromboembolic complications were more likely to appear after foam sclerotherapy on the lower leg (61/105) than on the thigh (1/13) (P < 0.001), particularly after dorsal than after ventral foam sclerotherapy (39 of 47 vs. 5 of 40, P < 0.001). Of the 39 thromboembolic complications on the dorsal lower leg, 23 were muscle vein thromboses. The risk of muscle vein thrombosis after foam sclerotherapy is especially increased in slender patients with sclerosed, dorsal lower legs.
Sections du résumé
BACKGROUND
Side effects of foam sclerotherapy for varicose veins can include both deep (DVT) and superficial leg vein thrombosis (SVT). The risk factors that favor the development of SVT or DVT after foam sclerotherapy are still largely unclear. The aim of our retrospective analysis was to use a larger group of patients with thromboembolic complications to identify both patient-related and procedure-related risk factors for thromboembolic complications from foam sclerotherapy.
PATIENTS AND METHODS
A total of 170 patients who received foam sclerotherapy were examined. With reference to a cut-off date, March 17th, 2020, the 85 most recent patients with thromboembolic complications (study group A) were included and compared to the most recent 85 patients without thromboembolic complications (control group B), after sclerotherapy with foamed sclerosant.
RESULTS
Patients with a thromboembolic complication were more likely to have thrombophilia (11/85 vs. 3/85). The mean BMI values in group A (25.9 ± 5.1) were significantly lower than in group B (28.0 ± 7.2) (P = 0.034). Thromboembolic complications were more likely to appear after foam sclerotherapy on the lower leg (61/105) than on the thigh (1/13) (P < 0.001), particularly after dorsal than after ventral foam sclerotherapy (39 of 47 vs. 5 of 40, P < 0.001). Of the 39 thromboembolic complications on the dorsal lower leg, 23 were muscle vein thromboses.
CONCLUSION
The risk of muscle vein thrombosis after foam sclerotherapy is especially increased in slender patients with sclerosed, dorsal lower legs.
Substances chimiques
Sclerosing Solutions
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
929-938Informations de copyright
© 2022 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.
Références
Rabe E, Breu F, Flessenkämper I et al. S2k-Leitlinie zur Sklerosierungsbehandlung der Varikosis. 2018. Available from: https://www.awmf.org/uploads/tx_szleitlinien/037-015l_S2k_Sklerosierungsbehandlung-Varikose_2019-05.pdf. [Last accessed September, 21, 2021].
Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol. 2003; 21: 3588-93.
Jia X, Mowatt G, Burr JM et al. Systematic review of foam sclerotherapy for varicose veins. Br J Surg 2007; 94: 925-36.
Cavezzi A, Parsi K. Complications of foam sclerotherapy. Phlebology. 2012; 27(Suppl 1): 46-51.
Gillet JL, Guedes JM, Guex JJ et al. Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1,025 patients. Phlebology 2009; 24: 131-8.
Hamel-Desnos CM, Guias BJ, Desnos PR, Mesgard A. Foam sclerotherapy of the saphenous veins: randomised controlled trial with or without compression. Eur J Vasc Endovasc Surg 2010; 39: 500-7.
Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg. 2005; 31: 123-8; discussion 28.
Labropoulos N, Mansour MA, Kang SS et al. New insights into perforator vein incompetence. Eur J Vasc Endovasc Surg. 1999; 18: 228-34.
Coleridge Smith P. Foam and liquid sclerotherapy for varicose veins. Phlebology 2009; 24(Suppl 1): 62-72.
Hamel-Desnos CM, Desnos PR, Ferre B, Le Querrec A. In vivo biological effects of foam sclerotherapy. Eur J Vasc Endovasc Surg 2011; 42: 238-45.
Myers KA, Jolley D, Clough A, Kirwan J. Outcome of ultrasound-guided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg 2007; 33: 116-21.
Lobastov K, Vorontsova A, Bargandzhiya A et al. The frequency and clinical significance of nontarget superficial and deep vein occlusion after physician compounded foam sclerotherapy of varicose tributaries. Phlebology 2020; 35: 430-9.
Kulkarni SR, Messenger DE, Slim FJ et al. The incidence and characterization of deep vein thrombosis following ultrasound-guided foam sclerotherapy in 1000 legs with superficial venous reflux. J Vasc Surg Venous Lymphat Disord 2013; 1: 231-8.
Myers KA, Jolley D. Factors affecting the risk of deep venous occlusion after ultrasound-guided sclerotherapy for varicose veins. Eur J Vasc Endovasc Surg 2008; 36: 602-5.
Cavezzi A, Frullini A, Ricci S, Tessari L. Treatment of varicose veins by foam sclerotherapy: two clinical series. Phlebology 2002; 17: 13-8.
Gerlach H, Hach-Wunderle V, Konstantinides S et al. Diagnostik und Therapieder Venenthrombose und der Lungenembolie. 2015. Available from: https://www.awmf.org/uploads/tx_szleitlinien/065-002l_S2k_VTE_2016-01.pdf. [Last accessed September 21, 2021].
Parsi K, Panozzo B, Bull A et al. Deep vein sclerosis following sclerotherapy: Ultrasonic and d-dimer criteria. Phlebology 2020; 35: 325-36.
Gillet JL, Lausecker M, Sica M et al. Is the treatment of the small saphenous veins with foam sclerotherapy at risk of deep vein thrombosis? Phlebology 2014; 29: 600-7.
Cheng YJ, Liu ZH, Yao FJ et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med 2013; 10: e1001515.
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
Kobus S, Reich-Schupke S, Pindur L et al. Ascending thrombophlebitis after foam sclerotherapy as first symptom of breast cancer. J Dtsch Dermatol Ges 2009; 7: 239-40.
Hamel-Desnos CM, Gillet JL, Desnos PR, Allaert FA. Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phlebology 2009; 24: 176-82.
Reich-Schupke S, Doerler M, Altmeyer P, Stücker M. Foam sclerotherapy with enoxaparin prophylaxis in high-risk patients with postthrombotic syndrome. Vasa 2013; 42: 50-5.
Sandri JL, Barros FS, Pontes S et al. Diameter-reflux relationship in perforating veins of patients with varicose veins. J Vasc Surg 1999; 30: 867-74.
Delis KT, Ibegbuna V, Nicolaides AN et al. Prevalence and distribution of incompetent perforating veins in chronic venous insufficiency. J Vasc Surg 1998; 28: 815-25.
Kulkarni SR, Slim FJ, Emerson LG et al. Effect of foam sclerotherapy on healing and long-term recurrence in chronic venous leg ulcers. Phlebology 2013; 28: 140-6.
Cho S, Gibson K, Lee SH et al. Incidence, classification, and risk factors of endovenous glue-induced thrombosis after cyanoacrylate closure of the incompetent saphenous vein. J Vasc Surg Venous Lymphat Disord 2020; 8: 991-8.
Engeli S, Stroh C. Adipositas und das Risiko für venöse Thrombosen und Embolien. Adipositas - Ursachen, Folgeerkrankungen, Therapie 2015; 09: 59-64.
Weill-Engerer S, Meaume S, Lahlou A et al. Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc 2004; 52: 1299-304.
Chindamo MC, Marques MA. Role of ambulation to prevent venous thromboembolism in medical patients: where do we stand? J Vasc Bras 2019; 18: e20180107.